Posts

GLP-1s and the Rise of Consumer-Led Pharma: What the Obesity Market Signals for the Future of Access

Most-Favored-Nation Drug Pricing: Policy Shift or Pressure Tactic?

Trump’s Drug Pricing Executive Order: Uncertainty for Pharma Leaders

Tariffs on Pharmaceuticals: Are Drug Prices Set to Rise?

Access To The New Alzheimer's Drugs: Why HTA Bodies Are Saying No

Taking on the access hurdles for orphan drugs: preparing for EU HTA

Disrupting HTA and HEOR: the role of AI